Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor

• Main Authors: Izadora Lorrany Alves Rabelo, Vanessa Fernandes Arnaud-Sampaio, Elena Adinolfi, Henning Ulrich, Claudiana Lameu
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Cells
• Subjects: cancer stem cells; stemness; P2X7 receptor; P2X7A; P2X7B; purinergic signaling
• Online Access: https://www.mdpi.com/2073-4409/10/7/1782

The heterogeneity of tumor cell mass and the plasticity of cancer cell phenotypes in solid tumors allow for the insurgence of resistant and metastatic cells, responsible for cancer patients’ clinical management’s main challenges. Among several factors that are responsible for increased cancer aggression, metabolic reprogramming is recently emerging as an ultimate cancer hallmark, as it is central for cancer cell survival and self-renewal, metastasis and chemoresistance. The P2X7 receptor, whose expression is upregulated in many solid and hematological malignancies, is also emerging as a good candidate in cancer metabolic reprogramming and the regulation of stem cell proliferation and differentiation. Metabostemness refers to the metabolic reprogramming of cancer cells toward less differentiated (CSCs) cellular states, and we believe that there is a strong correlation between metabostemness and P2X7 receptor functions in oncogenic processes. Here, we summarize important aspects of P2X7 receptor functions in normal and tumor tissues as well as essential aspects of its structure, regulation, pharmacology and its clinical use. Finally, we review current knowledge implicating P2X7 receptor functions in cancer-related molecular pathways, in metabolic reprogramming and in metabostemness.